Close

Vivus (VVUS) Qsymia Numbers Lowered at Needham & Company

April 11, 2014 6:30 AM EDT
Get Alerts VVUS Hot Sheet
Price: $0.47 --0%

Rating Summary:
    3 Buy, 6 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

Needham & Company analyst Alan Carr reiterated Hold rating and lowered estimates on Vivus (NASDAQ: VVUS) ahead of Q1 earnings and spring review.

Carr comments, "Qsymia prescriptions have remained relatively flat through 1Q14. Management indicated that the sales force reconfiguration process had a negative impact on sales in Jan and Feb. We continue to believe that patient awareness is a key factor for success in the weight loss space. The absence of a direct-to-consumer campaign at Vivus may therefore limit sales potential. We are reducing Qsymia sales estimates based on the latest prescription data."

The firm's new 1Q14 and 2014 Qsymia sales estimates are $7.5M (was $8.0M) and $55.5M (was $67.0M). Their new 2015 Qsymia sales estimate is $153.0M (was $198.0M).

For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.

Shares of Vivus closed at $4.91 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company, Earnings